Infliximab biosimilars get the EC approval

Infliximab biosimilars get the EC approval

Following the EMA’s CHMP recommendation in June, the European Commission has recently approved the first infliximab biosimilars, which are referenced to Remicade. Remsima/Inflectra which was developed by Celltrion Inc. of South Korea, has already shown to be similar to the biosimilar medicine Remicade, a monoclonal antibody that has been authorized in the EU since 1999.

Upcoming Events
Biologics World Nordic 2019 5 – 7 March 2019, Stockholm, Sweden

Biologics World Nordic will be the only focused biologic drugs and vaccines conference in the Nordic region. We will bring together the complete network of the Nordic biologics industry including region’s smaller Biopharma, Big Pharma, International Biopharma, CMOs, CROs, Technocrats & Solution Providers.

.. Read More

Biologics World Taiwan 2019 26 – 28 March 2019, Singapore

In March 2019, 7th Annual Biologics World Taiwan – the ONLY biologics and biosimilars focused platform in Taiwan – will again come to Taipei and bring together Taiwanese and international biopharma leaders, innovative biotechs, and technocrats!

.. Read More

Biologics Manufacturing Korea 2019 28 – 30 May 2019, Singapore

Since 2012, Biologics Manufacturing Korea has witnessed huge success in bringing over 550 biologics industry pioneers from both Korea and overseas. With the mission to facilitate development and manufacturing of high-quality biologic drugs and vaccines in Korea for the world market, Biologics Manufacturing Korea is going to continue its legacy.

.. Read More